Skip to main content
OpenTrials
Completed

NCT Number: NCT07122232

Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria

This study aimed to compare platelet count patterns in patients infected with either Plasmodium vivax or Plasmodium falciparum, the two most common malaria species in Pakistan. Thrombocytopenia (low platelet count) is a common complication of malaria and can help in identifying disease severity. We conducted this research at a tertiary care hospital in Peshawar, Pakistan, from April to September 2023. A total of 171 adult patients with confirmed malaria infections were enrolled. We measured their platelet counts at admission, day 3, and day 7, and analyzed the severity and progression of thrombocytopenia. The study found that while P. vivax was more common, P. falciparum was more likely to cause severe thrombocytopenia. Understanding these differences helps healthcare providers identify high-risk patients earlier and manage malaria more effectively. The study was approved by the institutional review board of Lady Reading Hospital, Peshawar.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Lady Reading Hospital, Medical Teaching Institution

Peshawar, KPK, 25000, Pakistan

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Microscopically confirmed infection with Plasmodium vivax or Plasmodium falciparum
  • Provided written informed consen

Exclusion criteria

  • Mixed-species malaria infection
  • Known hematologic disorders
  • Chronic liver disease
  • Recent blood transfusion
  • Use of anticoagulant medication
  • Incomplete parasitemia data or lost to follow-up

Treatment and study plan

Primary outcomes

  1. Proportion of patients with thrombocytopenia

    Time frame: 0 days

    The percentage of patients with platelet counts <50×10³/µL at admission, compared between the P. vivax and P. falciparum groups.

Secondary outcomes

  1. Platelet count recovery over time

    Time frame: Day 0 to Day 7

    Change in mean platelet count at admission, day 3, and day 7, for each group.

Other outcomes

  1. Frequency of malaria-related complications

    Time frame: Within 7 days of admission

    Number of patients developing clinical complications (e.g., acute kidney injury, neurological involvement, anemia, jaundice), stratified by malaria species.

Sponsors and collaborators

Lead sponsor

Rafiullah Hotak

Other

Collaborators

  • Lady Reading Hospital, Pakistan

Registry information

Official study title

Comparative Analysis of Thrombocytopenia in Plasmodium Vivax and Plasmodium Falciparum Malaria: A Prospective Cross-Sectional Study From a Tertiary Care Hospital in Peshawar, Pakistan

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 14, 2025
Registry last updated
Aug 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.